As of 2024-10-06, the EV/EBITDA ratio of PTC Therapeutics Inc (PTCT) is -541.29. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. PTCT's latest enterprise value is 4,432.66 mil USD. PTCT's TTM EBITDA according to its financial statements is -8.19 mil USD. Dividing these 2 quantities gives us the above PTCT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.6x - 16.9x | 14.9x |
| Forward P/E multiples | 16.8x - 19.1x | 17.6x |
| Fair Price | (24.31) - (24.32) | (24.26) |
| Upside | -169.3% - -169.3% | -169.1% |
| Date | EV/EBITDA |
| 2024-10-04 | -541.30 |
| 2024-10-03 | -543.83 |
| 2024-10-02 | -553.79 |
| 2024-10-01 | -550.22 |
| 2024-09-30 | -560.08 |
| 2024-09-27 | -564.40 |
| 2024-09-26 | -565.34 |
| 2024-09-25 | -555.76 |
| 2024-09-24 | -554.63 |
| 2024-09-23 | -556.79 |
| 2024-09-20 | -555.76 |
| 2024-09-19 | -551.25 |
| 2024-09-18 | -544.86 |
| 2024-09-17 | -541.01 |
| 2024-09-16 | -528.80 |
| 2024-09-13 | -530.87 |
| 2024-09-12 | -518.75 |
| 2024-09-11 | -514.71 |
| 2024-09-10 | -507.86 |
| 2024-09-09 | -506.73 |
| 2024-09-06 | -507.86 |
| 2024-09-05 | -508.42 |
| 2024-09-04 | -527.11 |
| 2024-09-03 | -525.42 |
| 2024-08-30 | -543.36 |
| 2024-08-29 | -545.33 |
| 2024-08-28 | -542.14 |
| 2024-08-27 | -543.36 |
| 2024-08-26 | -539.51 |
| 2024-08-23 | -532.37 |
| 2024-08-22 | -525.61 |
| 2024-08-21 | -530.31 |
| 2024-08-20 | -534.63 |
| 2024-08-19 | -535.28 |
| 2024-08-16 | -525.51 |
| 2024-08-15 | -521.95 |
| 2024-08-14 | -510.02 |
| 2024-08-13 | -510.96 |
| 2024-08-12 | -505.70 |
| 2024-08-09 | -505.51 |
| 2024-08-08 | -516.40 |
| 2024-08-07 | -510.77 |
| 2024-08-06 | -513.02 |
| 2024-08-05 | -502.78 |
| 2024-08-02 | -513.96 |
| 2024-08-01 | -518.66 |
| 2024-07-31 | -529.55 |
| 2024-07-30 | -521.85 |
| 2024-07-29 | -517.06 |
| 2024-07-26 | -531.81 |